We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Drug discovery and development- Dr. Wayne Carter
-
2. Chemical synthesis- Dr. Wayne Carter
-
3. In silico selection- Dr. Wayne Carter
-
4. In vitro drug screening
- Dr. Wayne Carter
-
5. Drug refinement- Dr. Wayne Carter
-
6. In vivo drug screening
- Dr. Wayne Carter
-
7. Drug pharmacokinetics- Dr. Wayne Carter
-
8. Clinical trials
- Dr. Wayne Carter
-
9. Intellectual property and patents
- Dr. Wayne Carter
Printable Handouts
Navigable Slide Index
Topics Covered
- Drug patent
- Intellectual property rules and regulations
- Drug development costs
- IP protection period
- Drug development economics
- Patent suitability
- Patent transfer
Links
Series:
Categories:
Talk Citation
Carter, W. (2026, April 30). Intellectual property and patents [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 1, 2026, from https://doi.org/10.69645/JSIM8767.Export Citation (RIS)
Publication History
- Published on April 30, 2026
Financial Disclosures
- There are no commercial/financial matters to disclose.